Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense.
Sepsis syndrome is frequently complicated by the development of nosocomial infections, particularly Gram-negative pneumonia. Although TNF-alpha (TNF) has been shown to mediate many of the pathophysiologic events in sepsis, this cytokine is a critical component of innate immune response within the lung. Therefore, we hypothesized that the transient transgenic expression of TNF within the lung during the postseptic period could augment host immunity against nosocomial pathogens. To test this, mice underwent 26-gauge cecal ligation and puncture (CLP) as a model of abdominal sepsis, followed 24 h later by intratracheal (i.t.) administration of Pseudomonas aeruginosa. In animals undergoing sham surgery followed by bacterial challenge, Pseudomonas were nearly completely cleared from the lungs by 24 h. In contrast, mice undergoing CLP were unable to clear P. aeruginosa and rapidly developed bacteremia. Alveolar macrophages (AM) recovered from mice 24 h after CLP produced significantly less TNF ex vivo, as compared with AM from sham animals. Furthermore, the adenoviral mediated transgenic expression of TNF within the lung increased survival in CLP animals challenged with Pseudomonas from 25% in animals receiving control vector to 91% in animals administered recombinant murine TNF adenoviral vector. Improved survival in recombinant murine TNF adenoviral vector-treated mice was associated with enhanced lung bacterial clearance and proinflammatory cytokine expression, as well as enhanced AM phagocytic activity and cytokine expression when cultured ex vivo. These observations suggest that intrapulmonary immunostimulation with TNF can reverse sepsis-induced impairment in antibacterial host defense.
Chen
G H
GH
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Reddy
R C
RC
Newstead
M W
MW
Tateda
K
K
Kyasapura
B L
BL
Standiford
T J
TJ
D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology; D000818:Animals; D021461:Animals, Outbred Strains; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000276:immunology; D002432:Cecum / Q000601:surgery; D002478:Cells, Cultured; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D005786:Gene Expression Regulation / Q000276:immunology; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007442:Intubation, Intratracheal; D008026:Ligation; D008168:Lung / Q000276:immunology* / Q000378:metabolism / Q000382:microbiology; D016676:Macrophages, Alveolar / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D051379:Mice; D020556:Neutrophil Infiltration / Q000276:immunology; D010587:Phagocytosis / Q000235:genetics; D018410:Pneumonia, Bacterial / Q000235:genetics / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D011552:Pseudomonas Infections / Q000235:genetics / Q000276:immunology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000254:growth & development / Q000276:immunology; D011677:Punctures; D016019:Survival Analysis; D018746:Systemic Inflammatory Response Syndrome / Q000235:genetics / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control*; D019076:Transgenes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis / Q000235:genetics*
D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha